GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes
Acta Diabetologica · 2024
DOI: 10.1007/s00592-024-02300-6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Diabetologica, 2024. Verfasst von Stefano Ciardullo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, Università degli Studi di Milano Bicocca, Milan, Italy. stefano.ciardullo@unimib.it. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Receptors, Gastrointestinal Hormone, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Milano - Bicocca.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 2 diabetes represents a growing challenge for global public health. Its prevalence is increasing worldwide, and, like obesity, it affects progressively younger populations compared to the past, with potentially greater impact on chronic complications. Dual glucagon like peptide 1 (GLP1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists are among the new pharmacological strategies recently developed to address this challenge. Tirzepatide, characterized by its ability to selectively bind and activate receptors for the intestinal hormones GIP and GLP-1, has been tested in numerous clinical studies and is already currently authorized in several countries for the treatment of type 2 diabetes and obesity. In this context, the aim of the present document is to summarize, in the form of a narrative literature review, the currently available data on the main mechanisms of action of GIP/GLP-1 co-agonists and the clinical effects of tirzepatide evaluated in various clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, Università degli Studi di Milano Bicocca, Milan, Italy. stefano.ciardullo@unimib.it.
- Department of Medicine and Rehabilitation, Policlinico di Monza, Via Modigliani 10, 20900, Monza, Italy. stefano.ciardullo@unimib.it.
- Unit of Metabolic Disease, University Hospital of Padua, Padua, Italy.
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- CISUP, Center for Instrument Sharing, University of Pisa, 56124, Pisa, Italy.
- Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, 88100, Catanzaro, Italy.
Förderung
- Università degli Studi di Milano - Bicocca
Zitieren
APA
Ciardullo, S., Morieri, M. L., Daniele, G., Fiorentino, T. V., Mezza, T., Tricò, D., Consoli, A., Del Prato, S., Giorgino, F., Piro, S., Solini, A., & Avogaro, A. (2024). GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes. Acta Diabetologica. https://doi.org/10.1007/s00592-024-02300-6
Vancouver
Ciardullo S, Morieri ML, Daniele G, Fiorentino TV, Mezza T, Tricò D, et al. GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes. Acta Diabetologica. 2024. doi:10.1007/s00592-024-02300-6
BibTeX
@article{Ciardullo2024,
author = {Ciardullo, Stefano and Morieri, Mario Luca and Daniele, Giuseppe and Fiorentino, Teresa Vanessa and Mezza, Teresa and Tricò, Domenico and Consoli, Agostino and Del Prato, Stefano and Giorgino, Francesco and Piro, Salvatore and Solini, Anna and Avogaro, Angelo},
title = {GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes},
journal = {Acta Diabetologica},
year = {2024},
doi = {10.1007/s00592-024-02300-6}
}
EUVIMED